<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140123</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP1601-18-02</org_study_id>
    <nct_id>NCT04140123</nct_id>
  </id_info>
  <brief_title>Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Dose-increasing, Placebo-controlled，Multi-dose, 28-day Continuous Administration Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, Efficacy, and PK of ZSP1601 in Patients With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Raynovent Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Raynovent Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK&#xD;
      characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic&#xD;
      steatohepatitis (NASH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Actual">August 3, 2021</completion_date>
  <primary_completion_date type="Actual">August 3, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses of ZSP1601 and placebo.</measure>
    <time_frame>Initiation of study treatment (Day 1) up to 2 weeks post-treatment.</time_frame>
    <description>severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI-PDFF</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>liver fat content with Magnetic resonance imaging proton density fat fraction (MRI-PDFF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>Tumor necrosis factor alpha level in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>serum Alanine Aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>serum Aspartate Aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>The time after dosing when Cmax occurs (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Maximum Contentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2z</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>t1/2z is defined as the time to decline half of the drug concentration in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac of Cmax</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Rac of ZSP1601 Peak Plasma Concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DF of ZSP1601 at steady status</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Multiple-dose plasma PK parameter: DF of ZSP1601 at steady status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast（AUC0-t）</measure>
    <time_frame>Baseline (0h) and day 14</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac of AUC</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>RAC of ZSP1601 Area under the plasma concentration versus time curve at steady state</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AUC(inf)</measure>
    <time_frame>Day1 and day 14</time_frame>
    <description>Area under the curve extrapolated until time is infinity (AUCinf)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Non-Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>ZSP1601-Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601-50mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601-Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601-50mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZSP1601-Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZSP1601-100mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601</intervention_name>
    <description>ZSP1601 tablets be taken orally for 28 days.</description>
    <arm_group_label>ZSP1601-Dose 1</arm_group_label>
    <arm_group_label>ZSP1601-Dose 2</arm_group_label>
    <arm_group_label>ZSP1601-Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1601 Placebo</intervention_name>
    <description>Subjects will receive matching placebo of ZSP1601</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>ZSP1601-Dose 1</arm_group_label>
    <arm_group_label>ZSP1601-Dose 2</arm_group_label>
    <arm_group_label>ZSP1601-Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are required to meet the following criteria in order to be included in the&#xD;
             trial:&#xD;
&#xD;
               1. Signature signed informed consent before the trial, and fully understood the&#xD;
                  content, process and possible adverse reactions.&#xD;
&#xD;
               2. Subjects must be willing and able to adhere to the visit schedule and protocol&#xD;
                  requirements and be available to complete the study.&#xD;
&#xD;
               3. Subjects(including partners)have no gestation plans and must use reliable methods&#xD;
                  of contraception during the study and until 6 months following the last dose of&#xD;
                  investigational product.&#xD;
&#xD;
               4. Male and female subjects aged 18-65 (including 18 and 65).&#xD;
&#xD;
               5. B ultrasound confirmed fatty liver.&#xD;
&#xD;
               6. NASH diagnosis or NASH phenotypic diagnosis.&#xD;
&#xD;
               7. Liver fat ≥10% at baseline (MRI-PDFF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible subjects must not meet any of the following exclusion criteria:&#xD;
&#xD;
               1. Excessive drinking for 3 consecutive months within 1 year before screening.&#xD;
&#xD;
               2. Allergic constitution.&#xD;
&#xD;
               3. Subjects who donated blood or bleeding profusely(&gt; 400 mL)in the 3 months&#xD;
                  preceding study screening.&#xD;
&#xD;
               4. Subjects having a history of bariatric surgery or preparing for bariatric surgery&#xD;
                  recently.&#xD;
&#xD;
               5. Subjects having a history of liver transplantation or plans for liver&#xD;
                  transplantation&#xD;
&#xD;
               6. Any diseases that increase the risk of bleeding, such as hemorrhoids, acute&#xD;
                  gastritis or gastric and duodenal ulcers.&#xD;
&#xD;
               7. Liver biopsy indicates cirrhosis or previous clinical diagnosis of cirrhosis.&#xD;
&#xD;
               8. Type 1 diabetes mellitus.&#xD;
&#xD;
               9. Uncontrolled type 2 diabetes mellitus (HbA1c≥8.0%)。&#xD;
&#xD;
              10. Any clinically significant abnormality upon physical examination or in the&#xD;
                  clinical laboratory tests, history or presence of other causes of liver&#xD;
                  disease,but not limited to above disorders: hepatitis b or hepatitis c virus&#xD;
                  (HCV) infection and chronic alcoholic liver disease, drug-induced liver disease,&#xD;
                  autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis,&#xD;
                  Wilson 's disease, alpha 1 - antitrypsin deficiency, liver, obvious abnormal&#xD;
                  liver function (ALT and AST acuity 5 x ULN or TBIL acuity 1.5 x ULN), etc.&#xD;
&#xD;
              11. Dysphagia or any medical history in gastrointestinal that interferes with the&#xD;
                  absorption of drugs.&#xD;
&#xD;
              12. History of having any special food(including dragon&#xD;
                  fruit,mango,grapefruit,etc.),strenuous exercises,or other factors may interfere&#xD;
                  with the absorption, distribution, metabolism, or excretion of drug within 2&#xD;
                  weeks prior to screening.&#xD;
&#xD;
              13. Participated in another clinical research study and received any investigational&#xD;
                  products within 3 months prior to dosing.&#xD;
&#xD;
              14. Presence of clinically significant abnormalities in ECG or QTcB&gt;450ms in males,or&#xD;
                  QTcB&gt;470ms in females.&#xD;
&#xD;
              15. HIV positive.&#xD;
&#xD;
              16. Clinically significant nephropathy or renal dysfunction, blood creatinine&#xD;
                  &gt;1.5×ULN, eGFR&lt; 60 mL/min/1.73m2 [calculation formula: Ccr:(140-age)× weight (kg)&#xD;
                  /0.818×Scr(mumol /L), female ×0.85].&#xD;
&#xD;
              17. Platelet count &lt;100×109/L.&#xD;
&#xD;
              18. Antinuclear antibody (ANA) confirmed positive and clinically significant.&#xD;
&#xD;
              19. Abnormal TSH with clinical significance.&#xD;
&#xD;
              20. Female during pregnancy and lactation or positive serum pregnancy test.&#xD;
&#xD;
              21. Patients with contraindication of MRI scan.&#xD;
&#xD;
              22. Take any product contains alcohol within 24 hours prior to dosing.&#xD;
&#xD;
              23. Have chocolate, any food or beverage that contains caffeine or xanthine within 24&#xD;
                  hours prior to dosing.&#xD;
&#xD;
              24. Positive for urine drug screening or history of substance abuse for a period of 5&#xD;
                  consecutive years before screening.&#xD;
&#xD;
              25. Any acute illness or concomitant medication from screening to first dosing.&#xD;
&#xD;
              26. As judged by the researcher, it is not suitable to join the clinical researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

